Seven Fleet Capital Management LP Invests $7.83 Billion in Xencor, Inc. $XNCR

Seven Fleet Capital Management LP acquired a new stake in Xencor, Inc. (NASDAQ:XNCR – Free Report) during the second quarter, Holdings Channel reports. The fund acquired 368,305 shares of the biopharmaceutical company’s stock, valued at approximately $7,828,524,000. Xencor comprises about 1.3% of Seven Fleet Capital Management LP’s holdings, making the stock its 17th largest holding.

Several other large investors have also modified their holdings of the business. ProShare Advisors LLC grew its holdings in shares of Xencor by 6.5% during the 4th quarter. ProShare Advisors LLC now owns 16,853 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 1,026 shares during the period. Cerity Partners LLC boosted its stake in Xencor by 3.8% during the fourth quarter. Cerity Partners LLC now owns 31,302 shares of the biopharmaceutical company’s stock worth $479,000 after buying an additional 1,143 shares during the period. State of Tennessee Department of Treasury boosted its stake in Xencor by 6.2% during the second quarter. State of Tennessee Department of Treasury now owns 30,721 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 1,784 shares during the period. CANADA LIFE ASSURANCE Co increased its position in shares of Xencor by 3.3% during the second quarter. CANADA LIFE ASSURANCE Co now owns 70,015 shares of the biopharmaceutical company’s stock valued at $550,000 after acquiring an additional 2,256 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Xencor by 118.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 3,018 shares during the last quarter.

Get Xencor alerts:

Xencor Stock Performance

Shares of Xencor stock opened at $28.44 on Thursday. The business has a 50-day simple moving average of $19.21 and a 200-day simple moving average of $14.57. Xencor, Inc. has a one year low of $7.80 and a one year high of $30.61. The company has a market cap of $2.11 billion, a PE ratio of -13.11 and a beta of 0.85.

Xencor (NASDAQ:XNCR – Get Free Report) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.51. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The firm had revenue of $51.22 million for the quarter, compared to analysts’ expectations of $18.89 million. During the same quarter last year, the company earned ($0.41) earnings per share. The firm’s revenue was up 17.4% compared to the same quarter last year. On average, sell-side analysts predict that Xencor, Inc. will post -3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on XNCR shares. Cantor Fitzgerald boosted their price target on shares of Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Wedbush boosted their target price on Xencor from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Truist Financial lowered their price target on Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. JPMorgan Chase & Co. boosted their price objective on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Monday, May 11th. Finally, Royal Bank Of Canada increased their target price on Xencor from $19.00 to $20.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Xencor has a consensus rating of “Hold” and an average price target of $24.86.

Check Out Our Latest Report on XNCR

Xencor Company Profile

(Free Report)

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

Featured Stories

• Five stocks we like better than Xencor
• Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
• Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
• Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
• Can Tesla’s Flying Roadster Distract From Its Real Risks?

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR – Free Report).

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.